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Complement factor HAge-related macular degeneration (AMD) is the leading cause of blindness in developed countries. It has been
proposed that the polymorphism encoding Y402H (T1277C) in the complement factor H gene (CFH) is one of
the main determinants of disease. We genotyped the polymorphism at a number of loci in the region
encompassing the Regulators of Complement Activation (RCA) on chromosome 1, including T1277C SNP, in
187 patients and 146 controls. Haplotypes have been classiﬁed as protective (P) or susceptible (S) with
respect to AMD. This included the identiﬁcation of an S haplotype with a T at 1277. The results show that no
single locus should be assumed to be directly responsible for AMD, but rather argue for the existence of RCA
haplotypes, which can be assigned meaningful predictive values for AMD. We conclude that the critical
sequences are within a region 450 kb centromeric to 128 kb telomeric of CFH.related macular degeneration;
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Polygenic diseases, such as Age-Related Macular Degeneration
(AMD), have proven difﬁcult to understand, at least partly because of
the complexity of the interactions between linked and unlinked genes,
the inﬂuence of noncoding polymorphisms affecting gene regulation,
variable age and sex related penetrance, and diverse environmental
factors [1–3]. These problems are compounded when the pathogenesis
is poorly understood.
AMD is one polygenic disease which appears to be amenable to
progress. There are at least several gene clusters involved, but inter-
estingly most (complement factor H (CFH), complement component 2
(C2), complement factor B (CFB), complement component 3 (C3),
mannose-binding lectin2 (MBL2))may relate to complementactivation
within vessels and may thus be understood in terms of functionalinteractions and quantitative effects [4–12]. At least some risk factors
are well known and contribute to a ﬁnal common pathway involving
inﬂammation and obstruction of terminal vasculature. Effective therapy
with anti vascular endothelial growth factor (VEGF) is available [13]
although genetic assays to identify those requiring treatment would be
helpful both clinically and ﬁnancially.
An unresolved series of problems relate to the multiplicity and
complexity of the genetic markers in the vicinity of CFH and to the
presence of some which may or may appear to contribute to either
susceptibility or protection. As one example of the confusion, Spencer et
al. [5] report contradictory results and suggest the use of the term
“inverse associations” until the pathophysiology is known. The same
group also discussed the difﬁculties resulting frommultiple comparisons
and from inferring rather than observing haplotypes [14].
A proven approach to evaluating disease associations has been
developed through studies of the Major Histocompatibility Complex
(MHC) [15–21]. The identiﬁcation of ancestral haplotypes (AH)
provides a means of studying the extensive coding and noncoding
sequences which have been selected through human evolution. These
are the sequences which are likely to bemost important in function and
disease. Ancestral haplotypes contain genomic structure, insertions and
deletions (indels), copy number variations (CNVs), and regulatory
elements as well as single nucleotide polymorphisms (SNPs) and
microsatellites. Thus potential complexity can be simpliﬁed resulting in
Table 1
Frequency and size of FH1 alleles in 187 AMD patients and 146 controls.
Size (bp) FH1 allele Allele frequency (%)
530 3 0·3
533 4 0·5
535 5 0.2
537 6 1·5
541 7 1·8
543 8 3·6
545 9 5·4
547 10 5·56
549 11 10·1
551 12 5·56
553 13 6·0
555 14 6·3
557 15 4·8
559 16 12·9
562 17 3·9
564 18 10·2
566 19 2·1
568 20 5·56
570 21 0·9
572 22 1·0
574 23 0·2
576 24 0·6
580 25 0·3
600 26 0·2
605 27 1·0
609 28 1·95
613 29 1·8
617 30 1·5
621 31 2·1
625 32 1·8
628 33 0·4
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susceptibility to disease.
Recently [22], we have characterised haplotypes of the beta block
of the RCA [23]. Here, we show that there are many more haplotypes
than described to date and that these can be classiﬁed as protective
(P) or susceptible (S) with respect to AMD. The P and S haplotypes
differ in several respects suggesting some explanations for the disease
association.
A potential clinical application is suggested by the fact that the PP
genotype is present in only 2% patients with AMD but 24% of controls.
Thus, a PP genotype may be useful in excluding the need for intensive
follow-up and treatment.2. Results and discussion
2.1. The polymorphic FH1 locus as the basis for classifying ancestral
haplotypes
The FH1 locus is highly polymorphic,withmore than30alleles found
in the333 subjects typed todate. Themore frequentalleles, designated7
through to 24, differ in amplicon length by approximately 2 base pairs
such that allele 7 is 541 bp, 8 is 543 bp, 9 is 545 bp, 10 is 547 bp etc., as
shown in Table 1.
To facilitate comparisons, the FH1 genotypes of all patients and
controls are displayed in a percentile database (Fig. 1). Subjects are
listed in approximate order of the gene frequency when the two
groups are combined. Patients with AMD are listed on the left together
with their clinical type and age. Controls are on the right. Most sub-
jects have 2 different alleles; those with only one are assumed to be
homozygous.Fig. 1. Genotypes of all individuals in the study represented as a percentile database. Alleles a
(when the 2 groups are combined). Patients with AMD are listed on the left together with th
alleles; those with only one are assumed to be homozygous. Alleles with a frequencyN5% (T
boxed with a dashed line. Alleles decreased in patients are boxed with a solid line.It is immediately clear that the AMD and controls have very different
allele frequencies. For example, in AMD, there are increases in FH1 16,
18, 14, 10, 20 and 12 but decreases in 11, 13, 9 and 17. Note that the
alleles increased in AMD are a set (10, 12, 14, 16, 18) reﬂecting a 4 base
difference in length (see Table 1). By contrast, the decreased alleles
belong to a different set (9, 11, 13, 17) also reﬂecting a 4 base difference
in length, but offset by 2 bases as shown in Table 1. The exception, FH1
15, is considered further below.
The alternating pattern of frequency is illustrated in Fig. 2 where it
can be seen that most alleles can be classiﬁed into one of the 2 groups
provisionally designated susceptibility (S) or protective (P) alleles.
Accordingly, each genotype could be assigned SS, SP or PP and in some
cases SX, PX or XX where the effect of X on AMD susceptibility is
unknown due to low allele frequency.
To test the validity of this approach we examined the trans-
interactions between S and P alleles. Initially we excluded lower
frequency alleles and selected the patients and controls with genotypes
restricted to the P alleles (11, 13) and S alleles (12 ,16, 20) which are
most signiﬁcantly increased or decreased as shown in Table 2 and Fig. 3.
Seventeen of the 21 controls have PP or PS. None of the patients
has PP. Note the PP, PS, SS distributions of 0·29, 0·52, 0·19 in controls
and 0, 0·37, 0·63 in AMD. These results suggest that P alleles are indeed
protective when homozygous and that S alleles are at least additive.
Very similar resultswereobtainedwhen the12most frequent alleles
were included in the analysis (Fig. 4). The P alleles (9, 11, 13, 17) and S
alleles (8, 10, 12, 14, 15, 16, 18, 20) gave PP, PS, SS distributions of 0·28,
0·47, 0·24 in controls and 0·02, 0·37, 0·61 in AMD. Only 3 of 137
patients are homozygous PP.
The classiﬁcation of lower frequency alleles given in Table 1 and
Fig. 2 is provisional but, when based on the odd and even rule, the
results are again similar with a maximal estimate for PP of 0·06 in
AMD. In controls, the gene frequencies of P and S again approximate
0·5 in Hardy Weinberg Equilibrium.2.2. Other loci deﬁne S and P haplotypes
Since it is known that the T1277C mutation is associated with AMD
and located close to the FH1 locus, we examined the relationship
between FH1 alleles and 1277 alleles. All of the S alleles (such as 10, 12,
14, 16, 18) carry C, whereas P alleles (9, 11, 13, 17) carry T. Interestingly,
FH115alsohas a T although it is increased rather thandecreased inAMD
and therefore cannot be classiﬁed as a P allele. In fact, 8 of the 18 AMD
patients with the TT genotype have FH1 15, conﬁrming that this
haplotype is distinctive. This ﬁnding suggests that neither the FH1 nor
the 1277 locus is directly involved in susceptibility or protection: alleles
may merely be imperfect markers in linkage disequilibrium with other
components on critical haplotypes.
In Fig. 5, the haplotypes including FH1 15 and T1277C are shown.
Note that 8 of the patients have TT conﬁrming that TT is not protective
in the presence of FH1 15. There are numerous potential haplotypes
when the −45 and +128 loci are included. Note the frequencies
of −45 6 (8/19 v 2/11) and +128 2 (11/19 v 3/11) alleles are the
principal differences between AMD and controls suggesting that
the −45 and +128 loci may be as important as the FH1 or 1277 loci
in marking the critical factors involved in protection and suscep-
tibility to AMD. If so, it is important to deﬁne the haplotypes rather
than alleles at any single locus.
In a previous study based on 3 generation families [22], 10
ancestral haplotypes of −45, 1277, FH1 and +128 were identiﬁed
including 5, T, 15, 1. As shown in Fig. 5, the patients have 6, T, 15, 1 or
5, T, 15, 2 rather than 5, T, 15, 1, suggesting that recombinationre listed on the top row. Subjects are listed in approximate order of the gene frequency
e clinical type and age. Controls are shown on the right. Most subjects have 2 different
able 2) in the combined groups have been boxed. The alleles increased in patients are
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Fig. 2. The allele frequencies (%) of the common FH1 alleles in AMD patients (n=187) and controls (n=146). Alleles designated susceptible are shown in green and protective
alleles are shown in red. The unbroken line represents the combined (patients and controls) allele frequency.
416 J.F. Williamson et al. / Genomics 98 (2011) 412–421centromeric or telomeric of CFH is responsible for the increased
frequencies of −45 6 and +128 2 in disease and for susceptibility
rather than protection. Note that −45 6, in the absence of T, 15, is not
associatedwithdisease, therefore implying that there are cis-interactions
with unidentiﬁed sequences marked by−45 6.2.3. AMD and diabetes
In a subset of the patients with AMD (n=46), the presence or
absence of type 2 diabetes (T2D) was known. The frequencies of FH1
in these patients are given in Fig. 6 which suggests that FH1 P alleles
such as 9 and 11 may not be protective for AMD in the presence of
diabetes. As expected, the frequencies in AMD patients without
diabetes are very similar to the total AMD group.Table 2
The F1 allele deﬁnes haplotypes with different levels of protection/susceptibility for
AMD. Only F1 alleles with frequencies N5% in the combined groups are shown.
F1 allele Controls
2n†=292
AMD
2n†=374
Combined groups
freq (%)
Odds ratio p‡
12 7 30 5·56 3·55 0·002
20 10 27 5·56 2·19 0·04
16 25 61 12·91 2·08 0·003
10 12 25 5·56 1·67 0·174
14 14 28 6·31 1·61 0·199
18 24 44 10·21 1·49 0·156
9 19 17 5·41 0·68 0·302
11 42 25 10·06 0·43 0·001
13 27 13 6·01 0·35 0·003
2n†=Number of haplotypes.
‡Fisher's exact 2-tailed probability.2.4. Clinical utility of FH1 and T1277C in excluding AMD
There have been suggestions that homozygous TT at 1277 may be
helpful in excluding AMD. However, in our current data set, the
negative predictive value of TT is too low to permit critical clinical
decisions. The beneﬁt of PP over TT as an excluding test is largely
due to the fact that the 6 TT genotypes including FH1 15 become PS
(see Fig. 4).
The present results argue for the existence of RCA beta haplo-
types which carry the sequences responsible for protection or sus-
ceptibility to AMD. No single locus, including 1277, should be assumed
to be directly responsible.
It is always hazardous to assign protection and susceptibility
alleles to a single locus since increased frequency of some alleles
must be compensated by reductions in others. In the present study,
however, we are conﬁdent that there are fundamental differences
between S and P haplotypes because, with the exception of FH1 15:
1. The distribution of SS, SP and PP in disease is not a simple function
of frequency.
2. Trans-interactions between S and P haplotypes are clearly
powerful, with S alleles dominating over P, although undoubtedly
complex.
In general, we are reluctant to ascribe signiﬁcance to HW distortion
in disease since this often reﬂects an inability to detect heterozygotes.
This is not the case in the present study.
Furthermore, with the exception of FH 15:
1. S and P alleles relate to sets determined by amplicon length.
2. S and P alleles relate to T1277C
3. Conclusions
Accordingly, we conclude that there are critical sequences in the
vicinity of the 1.7 Mb region between −45 to +128 and including
Fig. 3. FH1 genotype distribution in a subset of AMD and control individuals that carry combinations of common alleles that show statistically signiﬁcant, positive or negative,
association with AMD. Susceptible alleles are shown in green. Protective alleles are in red.
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plain the current results.
These sequences profoundly inﬂuence susceptibility to AMD.
Subjects with PP genotypes such as 11, 13 have a very low risk of
disease and sufﬁciently low to suggest that genetic typing may be
useful clinically. For the ﬁrst time it becomes possible to assign
meaningful predictive values or risks to particular genotypes. We
anticipate that further characterisation of RCA beta haplotypes will
enhance clinical utility.
Previously, we compared the sequences ampliﬁed from FH1 16
and 17 homozygotes and found that 16 and other S haplotypes had a
deletion of 2 bp plus multiple substitutions representing an SNP rate
of some 5% [22]. The 2 bp indel is found in sequences with a T at 1277
and appears to have arisen contemporaneously during primate
evolution. The length differences are largely a function of the number
of copies of diverse C and T rich tetramers inserted and deleted on
either side of the 2 bp indel. There are also more extensive indels
associated with S and P haplotypes.
Future studies will quantify the role and interactions between
haplotypes, examine the effect of more extensive RCA beta haplotypes
on therapeutic responses and perhaps assist in determining which
cases require early treatment.
In parallel with improved genetic typing, it will be valuable to
include other risk factors whichmay overcome the protective effect of
the PP genotype. A possible example is provided in the present data;
diabetesmay predispose to AMD in PP subjects, but further studies are
required to conﬁrm these results and determine whether the effect is
due to diabetes per se or further genetic interactions.
As argued here, the mechanism of disease protection is probably
quantitative and regulatory, since certain haplotypes are associated
with greater or lesser degrees of inﬂammation and vascular injury.
However qualitative changes in CFH itself may be also be important.
It seems likely that other products encoded in the region and in otherregions, such as the MHC, may also contribute. In these regards, AMD
will serve as a useful model for dissecting the contributions to poly-
genic diseases.
4. Materials and methods
4.1. Strategy
The intention is to determine the coding and noncoding sequences
which together determine susceptibility to, or protection from, a
polygenic disease. This resolves into the following steps.
Firstly, it is necessary to deﬁne multiple linked polymorphisms, and
particularly those which have numerous alleles, which can be detected
reliably. Combinations of alleles at contiguous loci allow the recognition
of candidate haplotypes. To have any value in studying disease and
control populations, these combinations must be observed rather than
inferred [24] and must be maintained through successive matings.
Operationally, an ancestral haplotype is deﬁned as a combination of
alleles which occurs:
1. as half the content of at least 3 different genotypes deﬁned in a
family study including at least 3 generations,
2. in at least 3 subjects not likely to be related by recent descent.
In such cases, it has been found that the entire sequence between
and beyond the component loci is identical, with the important
exception that some rapidly mutating microsatellites will exhibit
slippage. Thus the haplotype marks indels, CNVs, stable microsatellites
andSNPs and canbenumberedgenerally by reference to the component
allele at the most polymorphic locus, with a second digit to reﬂect the
order of discovery e.g. MHC AH8.1 [25].
Secondly, the extent of the haplotype is determined by locating the
boundaries deﬁned by recombination. As multiple examples are accu-
mulated, it is often possible to identify rare recombinants between
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Fig. 5. Alleles at −45 and +128 loci in FH1-15 individuals.
419J.F. Williamson et al. / Genomics 98 (2011) 412–421ancestral haplotypes at the more remote sites. These become useful in
mapping the contributions of the components [26,27].
Thirdly, it is possible to compare and contrast AHs and to classify
groups by virtue of their different effects in terms of susceptibility and
protection. Trans, cis and epistatic interactions can be deﬁned. The
validity of the groupings within the population can be tested using the
Hardy Weinberg equation.
In the present study, we have used the AHs deﬁned byWilliamson
et al. [22] to examine the effects in AMD and particularly the con-
tributions to susceptibility and protection.
4.2. Methods
The genomic region of 1.7 Mb containing CFH and its copies was
interrogated with multiple potential markers, including the T1277C
mutation in exon 9 of CFH and the FH1 polymorphism in intron 9. The
gene content and marker locations are shown in Fig. 7. By also using
the −45 and +128 markers ancestral haplotypes could be deﬁned.
All methods as Williamson et al. [22].
4.3. Patients and controls
The Centre for Eye Research Australia (RG and PNB) provided 187
AMD patients and 146 aged matched controls, which have been
described in previous studies [10,28]. All AMD participants were
recruited for the AMD inheritance study (AMDIS) from ophthalmology
clinics in Melbourne. Individuals were classiﬁed into clinical subsets
as 1. early (n=49), 2. geographic atrophy (GA; n=29) or subfoveal
choroidal neovascularisation (CNV; n=109). Controlswere collected as
part of the Visual Impairment Project (VIP), a population-based
epidemiological eye study or through aged-care nursing homes. All
individuals were of Anglo-Celtic ethnic background. On a subset of 35
control and 46 AMD individuals, additional clinical information was
available. This included the presence or absence of type 2 diabetes
(T2D).Fig. 4.Genotype distribution of FH1 alleles in those patients and controls that carry the 12mo
red. Subjects are sorted by allele frequencies within SS, SP and PP genotypes.Informed written consent was obtained from all individuals. Ethics
approval was provided by the Human Research and Ethics Committee
of the Royal Victorian Eye and Ear Hospital. The study was conducted
in accordance with the Declaration at Helsinki.Acknowledgments
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